Pembrolizumab in Refractory Metastatic Anal Cancer
Brief description of study
This research study is studying a targeted therapy as a possible treatment for advanced anal
The following intervention will be involved in this study:
Clinical Study Identifier: NCT02919969
Detailed Study Description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational drug to learn whether the drug works in treating a
specific disease. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab for Advanced
Anal Cancer, but it has been approved for other uses.
Pembrolizumab, also known as KEYTRUDA or MK-3475, is approved in the USA and several other
countries to treat a type of skin cancer called Malignant Melanoma.
In this research study the investigators are studying an investigational drug called
Pembrolizumab, which is a monoclonal antibody. Monoclonal antibodies are manmade and mimic
proteins in the immune system by attaching to specific proteins in the body. T cells are
cells in the immune system that are controlled by PD-1. PD-1 is a protein on the T cells
that prevent the body from overproducing T cells. Pembrolizumab targets PD-1, attaches to it
and blocks its action. By preventing PD-1 from working, T cell production rises and the
body's immune system may increase its action against Cancer cells. Clinical and laboratory
studies using pembrolizumab suggest that pembrolizumab may be useful in shrinking certain